Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes

Chemical Research in Toxicology

Volumn 9, Issue 4, 1996, Pages 800-806

  Usuki, Etsuko ^a   Pearce, Robin ^b   Parkinson, Andrew ^b   Castagnoli Jr , Neal ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CYTOCHROME P450; DRUG METABOLITE; HALOPERIDOL; KETOCONAZOLE; MONOCLONAL ANTIBODY; OXYGENASE; PYRIDINIUM DERIVATIVE; REDUCED HALOPERIDOL; TROLEANDOMYCIN;

ARTICLE; CONTROLLED STUDY; DRUG OXIDATION; DRUG TRANSFORMATION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME METABOLISM; LYMPHOBLASTOID CELL LINE; NEUROTOXICITY; SCHIZOPHRENIA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIBODIES; ANTIPSYCHOTIC AGENTS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HALOPERIDOL; HUMANS; KINETICS; MICROSOMES, LIVER; OXIDATION-REDUCTION; PYRIDINIUM COMPOUNDS; RATS; SPECTROMETRY, FLUORESCENCE; STEROID HYDROXYLASES;

FELIS CATUS; RODENTIA; STAPHYLOCOCCUS PHAGE 3A;

EID: 0030008439     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx960001y     Document Type: Article

References (53)

1. Tarsy, D., and Baldessarini, R. J. (1986) Movement disorders induced by psychotherapeutic agents. In Movement Disorders (Shah, N., and Donald, S., Eds.) pp 365-389, Plenum Press, New York.
2. Reynolds, G. P. (1992) Development in the drug treatment of schizophrenia. Trends Pharmacol. Sci. 13, 116-121.
3. Gerlach, J., and Casey, D. E. (1988) Tardive dyskinesia. Acta Psychiatr. Scand. 77, 369-378.
4. Oboyle, K. M., Gavin, K. T., and Harrison, N. (1993) Chronic antagonist treatment does not alter the mode of interaction of dopamine with rat striatal dopamine receptors. J. Recept. Res. 13, 1-4.
5. Glazer, W. M., Moore, D. C., Schooler, N. R., Brenner, L. M., and Morgenstern, H. (1984) Tardive Dyskinesia. Arch. Gen. Psychiatr. 42, 623-627.
6. Subramanyam, B., Rollema, H., Woolf, T., and Castagnoli, N., Jr. (1990) Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem. Biaphys. Res. Commun. 166, 238-244.
7. Fang, J., and Gorrod, J. W. (1991) Dehydration is the first step in the bioactivation of haloperidol to its pyridinium metabolite. Toxicol. Lett. 59, 117-123.
8. Chiba, K., Trevor, A. J., and Castagnoli, N., Jr. (1985) Metabolism of the neurotoxic tertiary amine MPTP by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120, 574-578.
9. Ottoboni, S., Carlson, T. J., Trager, W. F., Castagnoli, K., and Castagnoli, N., Jr. (1990) Studies on the cytochrome P-450 catalyzed ring a-carbon oxidation of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Chem. Res. Toxicol. 3, 423-427.
10. Nicklas, W. J., Vyas, I., and Heikkila, R. E. (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridinium, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 36, 2503-2508.
11. Vyas, I., Heikkila, R. E., and Nicklas, W. J. (1986) Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J. Neurochem. 46, 1501-1507.
12. + analogs and related charged species. J. Med. Chem. 33, 2221-2230.
13. Collins, M. A., Neafsey, E. J., Matsubara, K., Cobuzzi, R. J., and Rollema, H. (1992) Indole-N-methylated beta-carbolinium ions as potential brain bioactivated neurotoxins. Brain Res. 570, 1-2.
14. Youngster, S. K., Nicklas, W. J., and Heikkila, R. E. (1989) Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced neurotoxicity. II. Evaluation of the biological activity of the pyridinium metabolites formed from the monoamine oxidase-catalyzed oxidation of MPTP analogs. J. Pharmacol. Exp. Ther. 249, 828-835.
15. Saporito, M. S., Heikkila, R. E., Youngster, S. K., Nicklas, W. J., and Geller, H. B. (1992) Dopaminergic neurotoxicity of 1-methyl-4-phenylpyridinium analogs in cultured neurons: Relationship to the dopamine uptake system and inhibition of mitochondrial respiration. J. Pharmacol. Exp. Ther. 260, 1400-1409.
16. Bloomquist, J., King, E., Wright, A., Mytilineou, C., Kimura, K., Castagnoli, K., and Castagnoli, N., Jr. (1994) 1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: Cell culture and neurotransmitter uptake studies. J. Pharmacol. Exp. Ther. 270, 822-830.
17. Fang, J., and Yu, P. H. (1995) Effect of haloperidol and its metabolites on dopamine and noradrenaline uptake in rat brain slices. Psychopharmacology 121, 379-384.
18. +-like neurotoxicity of a pyridinium metabolite derived from haloperidol: In vivo microdialysis and in vitro mitochondrial studies. J. Pharmacol. Exp. Ther. 268, 380-387.
19. +) towards cultured dopaminergic neuroblastoma cells. Psychopharmacology 121, 373-378.
20. Forsmann, A., Folsch, G., Larsson, M., and Ohman, R. (1977) On the metabolism of haloperidol in man. Curr. Ther. Res. 21, 606-617.
21. 14C]-haloperidol in rats. Arzheim.-Forsch./Drug Res. 36, 443-452.
22. Pape, B. E. (1981) Isolation and identification of a metabolite of haloperidol. J. Anal. Toxicol. 5, 113-117.
23. Fang, J., and Gorrod, W. (1993) High-performance liquid chromatographic method for the detection and quantitation of haloperidol and seven of its metabolites in microsomal preparations. J. Chromatogr. 614, 267-273.
24. Subramanyam, B., Woolf, T., and Castagnoli, N., Jr. (1991) Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite.Chem. Res. Toxicol. 4, 123-128.
25. Igarashi, K., and Castagnoli, N., Jr. (1992) Determination of the pyridinium metabolite derived from haloperidol in brain tissue, plasma and urine by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. 579, 277-283.
26. Subramanyam, B., Pond, S. M., Eyles, D. W., Whitefold, A., Fouda, H. G., and Castagnoli, N., Jr. (1991) Identification of a potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol. Biochem. Biophys. Res. Commun. 181, 573-578.
27. Eyles, D. W., McLennan, H. R., Jones, A., McGrath, J. J., Stedman, T. J., and Pond, S. M. (1994) Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia. Clin. Pharmacol. Ther. 56, 512-520.
28. Van der Schyf, C. J., Castagnoli, K., Rimoldi, J. M., Usuki, E., Fouda, H. G., and Castagnoli, N., Jr. (1994) Metabolic studies on haloperidol and its tetrahydropyridine analog in C57BL/6 mice. Chem. Res. Toxicol. 7, 281-285.
29. Midha, K. M., Hawes, E. M., Hubbard, J. W., Korchinsky, E. D., and McKay, G. (1987) Interconversion between haloperidol and reduced haloperidol in humans. J. Clin. Psychopharmacol. 7, 362-364.
30. Janssen, P. A. J., Van de Westeringh, C., Jageneau, A. H. M., Demoen, P. J. A., Hermans, B. K. F., Van der Eycken, G. H. P., Schellekens, K. H. L., Van der Eycken, C. A. M., and Niemegeers, C. J. E. (1959) Chemistry and pharmacology of CNS depressants related to 4-(4-hydroxy-4-phenylpiperidino)butyrophenone: Part I-synthesis and screening data in mice. J. Med. Pharm. Chem. 1, 281-297.
31. Omura, T., and Sato, R. (1964) The carbon monoxide-binding pigment of liver microsomes. J. Biol. Chem. 239, 2370-2378.
32. Parkinson, A., and Gemzik, B. (1991) Production and purification of antibodies against rat liver P-450 enzymes. Methods Enzymol. 206, 233-245.
33. Dutton, D. R., and Parkinson, A. (1989) Reduction of 7-alkoxyresorufins by NADPH-cytochrome P450 reductase and its differential effects on their O-dealkylation by rat liver microsomal cytochrome P450. Arch. Biochem. Biophys. 268, 617-629.
34. Pearce, R., Greenway, D., and Parkinson, A. (1992) Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: Effects on coumarin, dicumarol, and testosterone oxidation. Arch. Biochem. Biophys. 298, 211-225.
35. Brian, W. R., Srivastava, P. K., Umbenhauer, D. R., Lloyd, R. S., and Guengerich, F. P. (1989) Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 28, 4993-4999.
36. Srivastava, P. K., Yun, C. H., Beaune, P. H., Ged, C., and Guengerich, F. P. (1991) Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol. Pharmacol. 40, 69-79.
37. Kronbach, T. (1991) Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450 IID6. Methods Enzymol. 206, 509-517.
38. Peter, R., Bocker, R., Beaune, P. H., Iwasaki, M., Guengerich, F. P., and Yang, C. S. (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem. Res. Toxicol. 3, 566-573.
39. Sonderfan, A. J., Arlotto, M. P., Dutton, D. R., McMillen, S. K., and Parkinson, A. (1987) Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch. Biochem. Biophys. 255, 27-41.
40. Halvorson, M., Greenway, D., Eberhart, D., Fitzgerald, K., and Parkinson, A. (1990) Reconstitution of testosterone oxidation by purified rat cytochrome P450p (IIIA1). Arch. Biochem. Biophys. 277, 166-180.
41. Romano, M. C., Straub, K. M., Yodis, L. A. P., Eckardt, R. D., and Newton, J. F. (1988) Determination of microsomal lauric acid hydroxylase activity by HPLC with flow-through radiochemical quantitation. Anal. Biochem. 170, 83-93.
42. In addition to the data reported in ref 34 on P450 2A and 3A, we have observed, but not yet published, similar cross reactivity with several other antibodies raised against rat P450s.
43. Eberhart, D. C., Gemzik, B., Halvorson, M. R., and Parkinson, A. (1991) Species differences in the toxicity and cytochrome P450 IIIA-dependent metabolism of digitoxin. Mol. Pharmacol. 40, 859-867.
44. Lemoine, A., Gautier, J. C., Azoulay, D., Loffe, L., Belloc, C., Guengerich, F. P., Maurel, P., Beaune, P., and Leroux, J. P. (1993) Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol. Pharmacol. 43, 827-832.
45. Gorrod, J. W., and Fang, J. (1993) On the metabolism of haloperidol. Xenobiotica 23, 495-508.
46. Bell, K., and Portoghese, P. (1973) Stereochemical studies on medicinal agents. 14. Relative stereochemistries and analgetic potencies of diastereomeric 3-allyl and 3-propyl derivatives of 1-methyl-4-phenyl-4-propionoxypiperidine. J. Med. Chem. 16, 203-205.
47. + found in rat brain following IP administration of HP. Life Sci. 57, 2439-2446.
48. Halpert, J. R., Guengerich, F. P., Bend, J. R., and Correia, M. A. (1994) Contemporary issues in toxicology: Selective inhibitors of cytochrome P450. Toxicol. Appl. Pharmacol. 125, 163-175.
49. Baldwin, S. J., Bloomer, J. C., Smith, G. J., Ayrton, A. D., Clarke, S. E., and Chenery, R. J. (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25, 261-270.
50. Schwab, G. E., Raucy, J. L., and Johnson, E. F. (1988) Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylation by α-naphthoflavone. J. Pharmacol. Exp. Ther. 33, 493-499.
51. Fabre, G., Julian, B., Saint-Aubert, B., Joyeux, H., and Berger, Y. (1993) Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab. Dispos. 21, 978-985.
52. Yun, C.-H., Okerholm, R. A., and Guengerich, F. P. (1993) Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Drug Metab. Dispos. 21, 403-409.
53. Coutts, R. T., Su, P., and Baker, G. B. (1994) Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 isozymes in N-dealkylation reactions. J. Pharmacol. Toxicol. Methods 31, 177-186.